A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease
Latest Information Update: 11 Jun 2025
At a glance
- Drugs Ianalumab (Primary)
- Indications Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 15 May 2025 Planned End Date changed from 8 Feb 2029 to 13 Feb 2029.
- 15 Jul 2024 Status changed from not yet recruiting to recruiting.
- 08 Apr 2024 Planned End Date changed from 5 Apr 2029 to 8 Feb 2029.